ADME Study of [14C] Yiqibuvir in Healthy Male Subjects
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05998304
- Locations
- 🇨🇳
Shanghai xuhui central hospital, Shanghai, Shanghai, China
A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT05802862
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 324
- Registration Number
- NCT05586074
- Locations
- 🇨🇳
the First Affiliated Hospital,College of Medicine,Zhejiang University, Hanzhou, China
A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT05576298
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Pharmacokinetics of Midazolam When Co-administered With HEC74647 and HEC110114
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT05504876
- Locations
- 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China
Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05497674
- Locations
- 🇨🇳
The First Hospital of Jilin University, Jilin, Changchun, China
Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC73077 in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 138
- Registration Number
- NCT05492630
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Study on the Body Mass Balance and Biotransformation of [14C]-HEC585
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05468346
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT05459285
- Locations
- 🇨🇳
PKUCare Luzhong Hospital, Zibo, Shandong, China
Clifutinib Food Effect Study in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05454098
- Locations
- 🇨🇳
the First Hospital of Jilin University, Changchun, Jilin, China
© Copyright 2024. All Rights Reserved by MedPath